Long‐Term Metabolic Consequences of Switching from Protease Inhibitors to Efavirenz in Therapy for Human Immunodeficiency Virus–Infected Patients with Lipoatrophy
Open Access
- 1 July 2002
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 35 (1) , 69-76
Abstract
The roles of nucleoside analogues and protease inhibitors (PIs) in the development of metabolic complications and fat-distribution abnormalities assoKeywords
This publication has 17 references indexed in Scilit:
- The HIV Protease Inhibitor Indinavir Decreases Insulin- and Contraction-Stimulated Glucose Transport in Skeletal MuscleDiabetes, 2001
- Metabolic effects of indinavir in healthy HIV-seronegative menAIDS, 2001
- Impact of Switching from Human Immunodeficiency Virus Type 1 Protease Inhibitors to Efavirenz in Successfully Treated Adults with LipodystrophyClinical Infectious Diseases, 2000
- Adverse effects of antiretroviral therapyThe Lancet, 2000
- Effects of Protease Inhibitors on Hyperglycemia, Hyperlipidemia, and LipodystrophyArchives of internal medicine (1960), 2000
- Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapyAIDS, 2000
- A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapyAIDS, 1999
- Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapineAIDS, 1999
- Visceral abdominal-fat accumulation associated with use of indinavirThe Lancet, 1998
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985